Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Andrology ; 7(6): 852-858, 2019 11.
Article in English | MEDLINE | ID: mdl-30993859

ABSTRACT

BACKGROUND: Nowadays, serodiscordant couples (SDCs) with human immunodeficiency virus (HIV) or hepatitis C virus (HCV)-infected men have the chance to conceive safely, giving birth with a minimum risk of cross-infection. OBJECTIVE: To assess the impact of male HIV and HCV infection on the assisted reproductive technologies (ART) outcomes in SDCs, with HIV or HCV seropositive men and negative partners. MATERIALS AND METHODS: Of 153 couples: 24 in Group 1 (HIV-seropositive men), 60 in Group 2 (HCV-seropositive men) and 69 in Group 3 (controls). Sperm-washing procedure was performed using a three-step system. Fresh ICSI cycles were carried out in HIV SDCs, HCV SDCs and controls. Seminal parameters, fertilization rate (FR), cleavage rate (CR), pregnancy rate per cycle (PR/C), miscarriage rate, implantation rate (IR) and live birth rate were evaluated. RESULTS: All the seropositive men have undetectable viral loads at the time of insemination, and both partners were free from co-morbid infections. The median number of embryos transferred was 2.0 (IQR 1.0-3.0), with no differences among groups. FR was significantly reduced in HIV and HCV SDCs compared to the controls (66%, 61% and 75%, respectively; p < 0.01). CR was similar between groups (p = 0.3). IR was 12.1%, 11.1% and 14.1%, respectively, in the three groups (p = 0.30). PR/C was 21.7%, 17.6% and 20.2% in HIV, HCV and controls, respectively. Live birth rate per cycle was 17.4%, 15.7% and 15.9%, respectively. There were no significant differences in clinical pregnancies per cycle, as well as miscarriages and live births (p = 0.30; 0.30; 0.60, respectively). CONCLUSIONS: The sperm-washing technique with ICSI may generate a promising way to improve pregnancy outcomes and to reduce the risk of viral transmission in these couples. In this setting, we can correctly counsel HIV- and HCV-infected men of SDCs with regard to the likelihood of father their own biological child.


Subject(s)
HIV Infections/prevention & control , HIV Infections/transmission , Hepatitis C/prevention & control , Hepatitis C/transmission , Reproductive Techniques, Assisted , Spermatozoa/virology , Adult , Case-Control Studies , Female , HIV/isolation & purification , HIV Seropositivity , Hepacivirus/isolation & purification , Humans , Male , Middle Aged , Pregnancy , Pregnancy Rate , Quality of Life , Risk , Viral Load , Young Adult
2.
Andrologia ; 50(7): e13022, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29687503

ABSTRACT

Azoospermia can be diagnosed in about 10%-15% of the infertile male population. To overcome the problem of failure to produce spermatozoa in the ejaculate in patients with nonobstructive azoospermia (NOA), testicular sperm extraction (TESE) may be performed to find the focal area of spermatogenesis. A 47-year-old man with NOA presented for treatment of secondary couple infertility. The patient underwent a first TESE 7 years earlier with cryopreservation, and an intracytoplasmic sperm injection-embryo transfer ended in a term pregnancy. He reported a history of repeated testicular traumas. At the present time, a complete medical workup was carried out, including clinical history, general and genital physical examination, scrotal and transrectal ultrasounds. Hormone measurements showed follicle-stimulating hormone level of 42.7 IU/L, luteinising hormone of 11.4 IU/L, total testosterone of 2.6 ng/ml and right and left testicular volume, respectively, of 4 and 3.9 ml. He underwent a second TESE, with successful sperm retrieval and cryopreservation. The histological pattern was hypospermatogenesis. In cases of extreme testicular impairment, although in the presence of very high follicle-stimulating hormone value and small testicular volume, estimating poor sperm recovery potential, the integration of clinical and anamnestic data, could help the surgeon to practise the more appropriate method of treatment.


Subject(s)
Azoospermia/diagnosis , Scrotum/diagnostic imaging , Sperm Retrieval , Testis/diagnostic imaging , Azoospermia/blood , Azoospermia/therapy , Estradiol/blood , Follicle Stimulating Hormone/blood , Humans , Luteinizing Hormone/blood , Male , Middle Aged , Prolactin/blood , Testosterone/blood , Treatment Outcome , Ultrasonography
3.
J Pept Res ; 60(6): 348-56, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12464113

ABSTRACT

The structural characterization of G-protein coupled receptors (GPCRs) is quite important as these proteins represent a vast number of therapeutic targets involved in drug discovery. However, solving the three-dimensional structure of GPCR has been a significant obstacle in structural biology. A variety of reasons, including their large molecular weight, intricate interhelical packing, as well as their membrane-associated topology, has hindered efforts aimed at their purification. In the absence of pure protein, available in the native conformation, classical methods of structural analysis such as X-ray crystallography and nuclear magnetic resonance spectroscopy cannot be utilized successfully. Alternative methods must therefore be explored to facilitate the structural features involved in drug-receptor interactions. The methods described herein detail the use of covalent probes, or affinity labels, capable of binding covalently to a target GPCR at its binding site(s). Our approach involves the incorporation of a number of reactive moieties in different regions of the ligand molecule each of which is expected to react with different amino acid residues. Information obtained from such work coupled with computer modeling and validated by the use of site-directed mutagenesis of GPCRs allows for three-dimensional mapping of the receptor binding site. It also sheds light on the different possible binding motifs for the various classes of agonists and antagonists and identifies amino acid residues involved with GPCR activation or inactivation.


Subject(s)
Photoaffinity Labels/chemistry , Receptors, Drug/chemistry , Amino Acids/metabolism , Animals , Binding Sites , Dronabinol/chemistry , Dronabinol/metabolism , GTP-Binding Proteins/chemistry , GTP-Binding Proteins/metabolism , Humans , Ligands , Molecular Probes/chemistry , Molecular Probes/metabolism , Photoaffinity Labels/metabolism , Protein Binding , Receptors, Cannabinoid , Receptors, Drug/metabolism , Structure-Activity Relationship , Tritium
4.
Biochem J ; 343 Pt 2: 397-402, 1999 Oct 15.
Article in English | MEDLINE | ID: mdl-10510306

ABSTRACT

Escherichia coli K1 CMP-sialic acid synthetase catalyses the synthesis of CMP-sialic acid from CTP and sialic acid. The active site of the 418 amino acid E. coli enzyme was localized to its N-terminal half. The bacterial CMP-sialic acid synthetase enzymes have a conserved motif, IAIIPARXXSKGLXXKN, at their N-termini. Several basic residues have been identified at or near the active site of the E. coli enzyme by chemical modification and site-directed mutagenesis. Only one of the lysines in the N-terminal motif, Lys-21, appears to be essential for activity. Mutation of Lys-21 in the N-terminal motif results in an inactive enzyme. Furthermore, Arg-12 of the N-terminal motif appears to be an active-site residue, based on the following evidence. Substituting Arg-12 with glycine or alanine resulted in inactive enzymes, indicating that this residue is required for enzymic activity. The Arg-12-->Lys mutant was partially active, demonstrating that a positive charge is required at this site. Steady-state kinetic analysis reveals changes in k(cat), K(m) and K(s) for CTP, which implicates Arg-12 in catalysis and substrate binding.


Subject(s)
Arginine/metabolism , Escherichia coli/enzymology , Lysine/metabolism , N-Acylneuraminate Cytidylyltransferase/metabolism , Amino Acid Motifs , Amino Acid Sequence , Amino Acid Substitution/genetics , Arginine/genetics , Binding Sites , Conserved Sequence/genetics , Cytidine Triphosphate/metabolism , Enzyme Stability , Escherichia coli/genetics , Kinetics , Lysine/genetics , Molecular Sequence Data , Mutagenesis, Site-Directed , N-Acylneuraminate Cytidylyltransferase/antagonists & inhibitors , N-Acylneuraminate Cytidylyltransferase/chemistry , N-Acylneuraminate Cytidylyltransferase/genetics , Oxidation-Reduction , Protein Denaturation , Pyridoxal Phosphate/metabolism , Recombinant Fusion Proteins/antagonists & inhibitors , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Sequence Alignment , Thermodynamics
5.
Zygote ; 7(1): 67-77, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10216919

ABSTRACT

Controlled ovarian stimulation was induced in 19 women for in vitro fertilisation/embryo transfer. After ovum pick-up, haptoglobin titres were determined by ELISA in sera and homologous follicular fluids. The haptoglobin phenotype of each subject was assessed and the penetration of the protein forms through the blood-follicle barrier was predicted on the basis of their molecular weight. The penetration threshold compatible with the barrier integrity was calculated as 92%, 73% and 57% of the blood level of phenotypes Hpt 1-1, Hpt 1-2 and Hpt 2-2 respectively. Penetration values comparable/lower or higher than threshold were found associated with 46 of 49 and 3 of 49 fertilised oocytes, respectively. Complexes of haptoglobin with apolipoprotein A-1 were isolated from follicular fluids by affinity chromatography with haemoglobin. The haptoglobin beta chain, after Western blotting and incubation with apolipoprotein A-1, was found to be involved in the protein-protein interaction as detected by anti-apolipoprotein A-1 antibodies. Complexes from separate fluids were analysed by electrophoresis and densitometry: the plain beta chain/apolipoprotein A-1 stoichiometric ratio was 0.75 and 1.40 in fluids associated with fertilised and unfertilised oocytes respectively. The results suggest that haptoglobin transport in the follicle depends on the integrity of the blood-follicle barrier and might be associated with oocyte quality, possibly by interfering with the role of apoliprotein A-1 in cholesterol or vitamin E exchange between high-density lipoproteins and granulosa cells.


Subject(s)
Apolipoprotein A-I/metabolism , Haptoglobins/metabolism , Oocytes/physiology , Ovarian Follicle/metabolism , Embryo Transfer , Enzyme-Linked Immunosorbent Assay , Female , Fertilization in Vitro , Haptoglobins/genetics , Humans , Oocytes/cytology , Phenotype , Protein Binding
6.
Mol Cell Endocrinol ; 95(1-2): 85-93, 1993 Sep.
Article in English | MEDLINE | ID: mdl-8243811

ABSTRACT

In the course of studies to elucidate the complex network of interactions controlling FRTL5 cell proliferation, thyroid stimulating hormone (TSH)-independent mutants (M cells), have been obtained from FRTL5 cells by chemical mutagenesis. In the present studies, the role of TSH on the proliferation and on differentiated and metabolic functions in these mutant cells have been investigated and compared to their response to insulin-like growth factor I (IGF-I). The addition of IGF-I to M cells leads to normal stimulation of DNA synthesis. However, inspite of the fact that mutant cells display normal TSH receptors, TSH is unable to stimulate the proliferation of the M cells. Nevertheless, TSH is able to increase intracellular levels of cAMP leading to regulation of TSH function in the M cells. On the other hand, TSH does not influence iodide transport and actin filaments depolimerization in these cells. However, aminoacid transport, stimulated in wild-type FRTL5 cells by both TSH and IGFs, is under the control of IGFs but not of TSH in the mutant cells. Neither TSH or IGF-I modified the expression of c-fos proto-oncogene in the M cells, probably because of high constitutive expression. These data suggest that a crucial signalling step(s) required for TSH induced mitogenesis is impaired in the M cells, and that this signalling step is not required for IGF-I induced mitogenesis.


Subject(s)
Cyclic AMP/physiology , Signal Transduction , Thyroid Gland/cytology , Aminoisobutyric Acids/metabolism , Animals , Biological Transport , Cell Differentiation/drug effects , Cell Line , DNA Replication/drug effects , Gene Expression Regulation/drug effects , Insulin-Like Growth Factor I/pharmacology , Iodides/metabolism , Proto-Oncogene Proteins c-fos/biosynthesis , Rats , Thyroid Gland/drug effects , Thyroid Gland/metabolism , Thyrotropin/metabolism , Thyrotropin/pharmacology
7.
J Cell Biol ; 108(2): 693-702, 1989 Feb.
Article in English | MEDLINE | ID: mdl-2537321

ABSTRACT

A specific surface receptor for urokinase plasminogen activator (uPA) recognizes the amino-terminal growth factor-like sequence of uPA, a region independent from and not required for the catalytic activity of this enzyme. The properties of the uPA receptor (uPAR) and the localization and distribution of uPA in tumor cells and tissues suggest that the uPA/uPAR interaction may be important in regulating extracellular proteolysis-dependent processes (e.g., invasion, tissue destruction). Phorbol myristate acetate (PMA), an inducer of U937 cell differentiation to macrophage-like cells, elicits a time- and concentration-dependent increase in the number of uPAR molecules as shown by binding, cross-linking, and immunoprecipitation studies. The effect of PMA is blocked by cycloheximide. Overall, the data indicate that PMA increases the synthesis of uPA. PMA treatment also causes a decrease in the affinity of the uPAR for uPA, thus uncovering another way of regulating the interaction between uPA and uPAR. In addition, the PMA treatment causes a modification of migration of the cross-linked receptor in mono- and bidimensional gel electrophoresis.


Subject(s)
Monocytes/metabolism , Receptors, Cell Surface/metabolism , Tetradecanoylphorbol Acetate/pharmacology , Cell Count , Cell Line , Cross-Linking Reagents , Electrophoresis, Polyacrylamide Gel , Enzyme Precursors , Humans , Immunosorbent Techniques , Molecular Weight , Peptide Fragments/metabolism , Plasminogen Activators/metabolism , Receptors, Cell Surface/biosynthesis , Receptors, Cell Surface/drug effects , Receptors, Urokinase Plasminogen Activator , Urokinase-Type Plasminogen Activator/metabolism
8.
J Biol Chem ; 263(5): 2358-63, 1988 Feb 15.
Article in English | MEDLINE | ID: mdl-2828365

ABSTRACT

The iodinated Mr approximately equal to 15,000 amino-terminal fragment (ATF) of the urokinase-type plasminogen activator (u-PA) molecule bound specifically to the cell surface of all of seven cultured human tumor cell lines studied. Cross-linking of iodinated ATF to the cell surface using a bifunctional amino-reactive reagent followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography revealed with the four cell lines studied the occurrence of a single band migrating with an Mr of 70,000-75,000, indicating complex formation with an Mr of 55,000-60,000 u-PA receptor protein (u-PA-R). In the human monocyte cell line U937 cultivated in the presence of phorbol ester, the amount of complex was strongly increased, and a fraction of the complex had a slower electrophoretic mobility. Comparison between autoradiograms of reduced and unreduced samples suggests that u-PA-R consists of one polypeptide chain. Two forms of u-PA-R, which differed with respect to affinity to concanavalin A, were identified. u-PA-R retained its ability to bind to ATF after cell lysis, and it was purified approximately 2,200-fold from biosynthetically labeled U937 cells by affinity chromatography with proenzyme u-PA coupled to Sepharose. The purified Mr 55,000-60,000 protein was specifically bound and cross-linked to u-PA, proenzyme u-PA, and ATF, but not to tissue-type plasminogen activator or other unrelated proteins.


Subject(s)
Plasminogen Activators/metabolism , Receptors, Cell Surface/metabolism , Tumor Cells, Cultured/metabolism , Urokinase-Type Plasminogen Activator/metabolism , Electrophoresis, Polyacrylamide Gel , Humans , Kinetics , Molecular Weight , Receptors, Cell Surface/isolation & purification , Receptors, Urokinase Plasminogen Activator
9.
Endocrinology ; 120(2): 785-90, 1987 Feb.
Article in English | MEDLINE | ID: mdl-2948816

ABSTRACT

In previous studies we have shown that insulin-like growth factor I (IGF-I) has a mitogenic effect in a line of rat thyroid follicular cells, the FRTL-5. In view of this effect, we undertook studies to identify and characterize some physicochemical and binding properties of the receptor for IGF-I in these cells and to determine what role it plays in the mitogenic activity of insulin and insulin-like growth factors in the FRTL-5 cell. Binding of 125I-labeled IGF-I (biosynthetic Thr59-IGF-I) to FRTL-5 was a function of time, temperature, and pH and was completely inhibited by high concentrations of unlabeled IGF-I. Scatchard plots of four saturation studies revealed a single apparent binding site with an average Ka of 4.2 +/- 0.6 X 10(9) M-1 (mean +/- SD) and an average maximum binding capacity of 20 +/- 2 pm/100 micrograms cellular protein. Rat IGF-II (rIGF-II) and insulin were far less potent that IGF-I in inhibiting the binding of [125I] IGF-I, and bovine TSH was without effect. 125I-Labeled IGF-II also bound to FRTL-5 cells. Binding was completely inhibited by unlabeled rIGF-II and, with lesser potency, by IGF-I. Even at high concentrations, insulin failed to inhibit the binding of [125I]IGF-II. Disuccinimidyl suberate cross-linked [125I]IGF-I to a moiety in FRTL-5 that had an apparent mol wt of approximately 135,000, as judged from sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. Cross-linking of [125I]IGF-I was inhibited in a dose-dependent manner by unlabeled IGF-I and, with far lower potency, by rIGF-II and insulin. All three peptides stimulated the incorporation of [3H]thymidine into the DNA of FRTL-5 cells, IGF-I being the most potent, followed in decreasing order of potency of rIGF-II and insulin. The mitogenic activities of these polypeptides correlated well with their abilities to inhibit the binding of [125I]IGF-I. These data indicate that the FRTL-5 cell possesses a receptor for IGF-I that resembles in its binding and physicochemical properties the receptor for IGF-I in other tissues (type I IGF receptor) and that mediates the mitogenic response to IGF-I and insulin in these cells. FRTL-5 cells also contain a receptor for IGF-II (type II IGF receptor), but its role vis-à-vis that of the type I IGF receptor in relation to the mitogenic effect of IGF-II in these cells is uncertain.


Subject(s)
Insulin-Like Growth Factor I/metabolism , Receptor, Insulin/metabolism , Somatomedins/metabolism , Thyroid Gland/metabolism , Animals , Cell Line , DNA Replication , Kinetics , Rats , Receptor, Insulin/isolation & purification , Receptors, Somatomedin , Sodium Chloride/pharmacology
10.
Am Ind Hyg Assoc J ; 41(8): 592-4, 1980 Aug.
Article in English | MEDLINE | ID: mdl-7405828

ABSTRACT

Allied Chemical Corporation, Specialty Chemicals Division industrial hygienists required an accurate, convenient method for the sampling and analysis of dinitrotoluene vapor concentrations in the workplace air. A method has been developed which combines collection of dinitrotoluene vapor onto silica gel sample tubes, desorption in chloroform, and gas chromatographic determination of the various isomers of dinitrotoluene. Concentrations of less than 10 percent of the TLV can be determined in a 50 liter air sample.


Subject(s)
Air Pollutants, Occupational/analysis , Air Pollutants/analysis , Dinitrobenzenes/analysis , Nitrobenzenes/analysis , Chromatography, Gas/instrumentation
SELECTION OF CITATIONS
SEARCH DETAIL
...